BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAK7. A total of 46 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,491,929 | -1.5% | 9,582,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $9,632,880 | +5.0% | 9,582,000 | +8.9% | 0.00% | 0.0% |
| Q1 2023 | $9,178,488 | -2.9% | 8,800,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $9,456,128 | +40.0% | 8,800,000 | +29.4% | 0.00% | +50.0% |
| Q3 2022 | $6,753,000 | +13.2% | 6,800,000 | +13.3% | 0.00% | 0.0% |
| Q2 2022 | $5,963,000 | +32.3% | 6,000,000 | +33.3% | 0.00% | +100.0% |
| Q1 2022 | $4,506,000 | – | 4,500,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wellesley Asset Management | 30,062 | $30,276,000 | 2.06% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 45,103,000 | $45,311,000 | 0.72% |
| MACKAY SHIELDS LLC | 76,920,000 | $77,403,000 | 0.68% |
| LOOMIS SAYLES & CO L P | 2,277,794 | $175,618,000 | 0.24% |
| KBC Group NV | 300,000 | $30,339,000 | 0.11% |
| CAMDEN ASSET MANAGEMENT L P /CA | 3,200,000 | $3,204,000 | 0.10% |
| Allianz Asset Management GmbH | 116,770,000 | $118,163,000 | 0.09% |
| PALISADE CAPITAL MANAGEMENT, LP | 3,143,000 | $3,168,000 | 0.07% |
| Lombard Odier Asset Management (Europe) Ltd | 1,600,000 | $1,610,000 | 0.06% |
| THRIVENT FINANCIAL FOR LUTHERANS | 16,400,000 | $16,421,000 | 0.03% |